-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisavanbulin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisavanbulin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisavanbulin in Triple-Negative Breast Cancer (TNBC) Drug Details: Lisavanbulin (BAL-101553)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Obsessive-Compulsive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Obsessive-Compulsive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Obsessive-Compulsive Disorder Drug Details: Rituximab (MabThera, Rituxan, Ristova) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisavanbulin in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisavanbulin in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisavanbulin in Glioblastoma Multiforme (GBM) Drug Details: Lisavanbulin (BAL-101553) is under...
-
Sector Analysis
Colombia Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Columbia Defense Market Report Overview As of 2024, the Columbia defense budget is worth $13.7 billion. The country’s defense budget is expected to grow at a CAGR of more than 6% during 2025-2029. Border disputes, continuous human rights violations, and terrorism are the major drivers for defense expenditure. In 2017, the Venezuelan Armed Forces invaded and forcefully occupied a small part of the Colombian territory in the border area separated by the Arauca River. Columbia Defense Market Outlook, 2024-2029 ($...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisavanbulin in High-Grade Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lisavanbulin in High-Grade GliomaDrug Details:Lisavanbulin (BAL-101553) is under development for the treatment of advanced or recurrent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:Rituximab (MabThera,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Schizophrenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Rituximab in Schizophrenia Drug Details:Rituximab (MabThera, Rituxan, Ristova) is an anti-neoplastic agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNB-738 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNB-738 in Autoimmune Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TNB-738 in Autoimmune Disorders Drug Details:TNB-738 is under development for the treatment of...